Cargando…

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi

BACKGROUND: The aim of this study is to compare the effectiveness of (131)I therapy between three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation after total thyroidectomy and were postoperatively judged with low risk of cancer recurrence. METHODS: The project was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kukulska, Aleksandra, Krajewska, Jolanta, Gawkowska-Suwińska, Marzena, Puch, Zbigniew, Paliczka-Cieslik, Ewa, Roskosz, Jozef, Handkiewicz-Junak, Daria, Jarzab, Michał, Gubała, Elzbieta, Jarzab, Barbara
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989933/ https://www.ncbi.nlm.nih.gov/pubmed/21040579 http://dx.doi.org/10.1186/1756-6614-3-9

Ejemplares similares

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2009)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma
por: Kukulska, Aleksandra, et al.
Publicado: (2019)

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
por: Krajewska, Jolanta, et al.
Publicado: (2020)

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer
por: Kukulska, Aleksandra, et al.
Publicado: (2021)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer
por: Ledwon, Aleksandra, et al.
Publicado: (2021)

Lobo-isthmectomy in the management of differentiated thyroid cancer
por: Krajewska, Jolanta, et al.
Publicado: (2023)

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2020)

Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision
por: Czarniecka, Agnieszka, et al.
Publicado: (2010)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

Comparison of clinical examination with orbital MRI evaluation in patients with thyroid orbitopathy - do we need imaging and when?
por: Król, Aleksandra, et al.
Publicado: (2013)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

Gene signature of the post-Chernobyl papillary thyroid cancer
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2016)

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
por: Pacini, Furio, et al.
Publicado: (2021)

Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves’ disease
por: Zaman, Maseeh uz, et al.
Publicado: (2015)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017)

Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages
por: Warakomski, Jakub, et al.
Publicado: (2018)

Gene Expression from Bronchoscopy Obtained Tumour Samples as a Predictor of Outcome in Advanced Inoperable Lung Cancer
por: Suwinski, Rafal, et al.
Publicado: (2012)

A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping
por: Fujarewicz, Krzysztof, et al.
Publicado: (2007)

Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020)

Treatment of advanced thyroid cancer refractory to therapy
por: Jarząb, Barbara
Publicado: (2013)

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
por: Wojtas, Bartosz, et al.
Publicado: (2017)

Introduction to European comments on “Medullary Thyroid Cancer: management guidelines of the American Thyroid Association”
por: Jarzab, Barbara, et al.
Publicado: (2013)

Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
por: Pitoia, Fabián, et al.
Publicado: (2012)

Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer
por: Ha, Seunggyun, et al.
Publicado: (2015)

Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
por: Krčálová, Eva, et al.
Publicado: (2020)

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review
por: Ansari, Mojtaba, et al.
Publicado: (2022)

Welcome to Thyroid Research
por: Lewinski, Andrzej, et al.
Publicado: (2008)

Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?
por: Czarnocka, B, et al.
Publicado: (2001)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
por: Rusinek, Dagmara, et al.
Publicado: (2018)

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
por: Shi, Liang, et al.
Publicado: (2022)

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
por: Gawlik, Tomasz, et al.
Publicado: (2010)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
por: Qiu, Xian, et al.
Publicado: (2022)

Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
por: Soyluoglu, Selin, et al.
Publicado: (2023)

SAT525 Long-Term Outcomes in Stage I Thyroid Cancer Without Radioiodine Remnant Ablation
por: Mubeen, Faiza, et al.
Publicado: (2023)

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010
por: Rachinsky, I., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k6slda76buf3tvl3ihgn4tob01